Bayer’s K9 Advantix II has Joined Forces with K9s For Warriors

Bayer’s K9 Advantix II is supporting K9s For Warriors with a three month campaign that allows dog owners to provide assistance to K9s For Warriors when people purchase Bayer’s K9 Advantix II. This is the second year for the partnership. When pet owners buy a package of K9 Advantix II, Bayer will donate $1 to K9s For Warriors to a maximum of $150,000. Bayer’s K9 Advantix II will also support the adoption and training of 10 service dogs in 2015.

According to the United States Department of Veterans Affairs approximately 20% of post 9/11 veterans suffer from post-traumatic stress disorder (PTSD) or traumatic brain injuries (TBI). Symptoms of PTSD include flashbacks, memory problems, self-destructive behaviour, and suicide. Symptoms of TBI are concentration difficulties, difficulty speaking, and emotional and behavioural changes.

K9s For Warriors is a nonprofit organization that pairs trained shelter dogs with veterans afflicted by post-traumatic stress disorder and/or traumatic brain injury. K9s For Warriors selects dogs from shelters and trains the dogs at their facility to become service dogs. Once the dogs are trained, they are matched with veterans in need of help. Once gaining a service dog, 92% of veterans are able to decrease or stop their medications. The program has a 96% success rate which the program attributes to their requirement for new service dog owners to live and train with their dogs at the K9s For Warriors facility before taking the dog home.

READ THE NEWS REPORT

Will Zoetis be gobbled up by Bayer?

Consolidation continues in the Pharmaceutical industry

A recent article in Bloomberg News argues the case for such an acquisition. 

Bloomberg places Zoetis No. 1 in the global animal-health business, with $4.56 billion in revenue last year. Bayer is in fifth place, with 1.31 billion euros in last year’s sales after Merck & Co. (MRK), Sanofi (SAN) and Eli Lilly.

Read the article

Bayer plans to focus entirely on Life Science businesses

Bayer announced last week it intends to focus entirely on the Life Science business - HealthCare and CropScience - and float MaterialScience on the stock market as a separate company. This move will position Bayer as a world-leading company in the field of human, animal and plant health. 

"Our intention is to create two top global corporations: Bayer as a world-class innovation company in the Life Science businesses, and MaterialScience as a leading player in polymers," said Bayer CEO Dr. Marijn Dekkers. He added that both companies have excellent prospects for success in their respective industries. 

The plan was unanimously approved by the Supervisory Board 18 September. It is expected that Bayer's MaterialScience business will be floated on the stock market by 2016 at the latest. Planned separation will benefit both Bayer and MaterialScience. The companies of the future Bayer Group had pro forma sales of approximately EUR 29 billion in 2013. they will employ nearly 99,000 people. Corporate headquarters will remain in Leverkusen. 

READ THE NEWS RELEASE

Bayer releases 2014 Q1 Financial Report

Bayer released its first quarter financial report this week and the pharmaceutical company is reporting encouraging growth in its sales and earnings. 

Gross cash flow in the first quarter of 2014 rose by 13.3% to €2,048 million due to the improvement in EBITDA. Net cash flow, however, declined to €163 million because more cash was tied up in working capital. 

Net financial debt rose from €6.7 billion on December 31, 2013, to €9.1 billion on March 31, 2014. This increase was driven by the acquisition of Algeta ASA, Norway. 

Sales of the Animal Health Division rose by 8.0% to €330 million. Business with our Advantage™ line of flea, tick and worm control products developed particularly well. 

READ THE REPORT 

Bayer continues positive business momentum

The Bayer Group continued its positive business momentum in the third quarter of 2013 with substantial contributions from the Life Science, Healthcare and CropScience sectors. 

"Healthcare registered encouraging growth, largely due to the outstanding sales performance for our new pharmaceutical products," said Bayer Management Board Chairman, Dr. Marijn Dekkers. 

After currency and portfolio adjustments, reported sales of the Bayer Group grew by 6.0%. Earnings before interest and tax improved by a substantial 47.5% to EUR 1,221 million. Gross cash flow moved ahead by 35.9% to EUR 1,367 million, mainly as a result of the significant improvement in EBIT. Net cash flow fell by 13.0% to EUR 1,728 million because less working capital was released than in the prior-year quarter. Net financial debt declined from EUR 9.0 billion on June 30, 2013 to EUR 7.7 billion on Sept. 30, 2013, largely as a result of cash inflows from operating activities. 

For the full report, visit BAYER INVESTOR RELATIONS

Bayer HealthCare Launches New Advertising Campaign

Bayer HealthCare announced April 10, 2012 the launch of their new advertising campaign starting this spring that will target Canadian pet owners, more specifically cat and dog owners, on the importance of effective flea control.

The campaign will encourage pet owners to speak with their veterinarians about prevention and the possible risks that flea's could have on their pets.

Click the following link to read the official Press Release:

• Bayer Launches Advertising Campaign for Pet Owners

Year of the Cat booth at OVMA/AAHA garners lots of interest

Dr. Elizabeth Obrien provides yet another interview in front of the Year of the Cat booth at Canada's largest gathering of animal health stakeholders in Toronto last week.

This national initiative arose out of the International Summit for Urban Animal Strategies in 2009 which focused on the plight of cats in our communities. 

This is the first Summit program to embrace all stakeholders and to be supported by all four sectors of the industry Animal Welfare, Animal Health and Wellness, Animal Control and Enforcement, and Animal Services.

PetLynx, Petsecure, PetSmart Charities and Ontario SPCA were the initial sponsors of this initiative, but it has now found widespread support across the industry led by the tireless efforts of Dr. Obrien, Judi Cannon, PetLynx and Mika Sanson, PetSecure as well as Kate McDonald and her ever helpful colleagues at Ontario SPCA. Brand affiliations include Iams by Procter and Gamble and Profender by Bayer who have added their resources to promote this program across Canada.

The OVMA/AAHA booth was resourced by Judi Cannon, Dr. Liz and the wonderful Stephanie Johns of the Ontario SPCA.  To read more about this initiative or to bring the Year of the Cat program to your community please visit Care for Cats or contact  judi.cannon@petlynxmail.com